APAC Multiple Sclerosis Drugs Market

APAC Multiple Sclerosis Drugs Market Size (2024 to 2029)

The APAC multiple sclerosis drugs Market was worth USD 6.56 billion in 2024 and is estimated to be growing at a CAGR of 9.34%, to reach USD 10.25 billion by 2029.

Multiple sclerosis is a chronic, inflammatory, autoimmune disease that affects the central nervous system (CNS), particularly the communication between the brain and other areas of the body.

During the forecast period, the APAC  multiple sclerosis drugs market is expected to develop due to an increase in the number of patients, increasing screening, and the demand for better care alternatives. The disease is more common in older people, thus the rise in the geriatric population is fuelling the expansion of the multiple sclerosis drug market. Clinical research and R&D investment are attracting a lot of attention on the market.

Many pharmaceutical companies are concentrating their efforts on creating new treatments for multiple sclerosis. Increased research efforts have also created the path for a slew of research agreements between pharmaceutical corporations and research institutes, benefiting the industry even more. Increased research on diverse novel candidates has resulted in the pipeline portfolios of both large and small pharmaceutical businesses being strengthened. The anticipated launch of these pipeline candidates is projected to fuel the growth of the APAC multiple sclerosis drugs market. The burden of MS(multiple sclerosis) is growing at an alarming rate, causing anxiety among healthcare practitioners and governments alike.

As the disease's prevalence has increased, several governments have been forced to take proactive steps in the form of guidelines and recommendations. Aside from that, government organizations are launching numerous public awareness campaigns to educate patients about the many treatment alternatives available. For people with MS, the American Academy of Neurology (AAN) has developed a number of guidelines for initiating, switching, and discontinuing disease-modifying treatments (DMTs). Some other primary drivers of the MS medicines market are the significant unmet need for therapies to treat the disease and the large R&D pipelines.

Furthermore, increased research in the field of MS to find novel therapeutics has propelled the MS pharmaceuticals market's rise. Several pharmaceutical companies are conducting clinical trials for the treatment of multiple sclerosis. Companies are attempting to develop novel treatments for individuals suffering from multiple sclerosis radiology, which is propelling the APAC multiple sclerosis drugs market forward.

However, The high cost of pharmaceuticals used to treat multiple sclerosis (MS) restricts the market's growth. MS is an incurable disease that requires lifelong treatment due to the significant risk of disability. Despite tight rivalry among pharmaceutical companies, MS(Multiple Sclerosis) drugs remain expensive, increasing the entire cost of treatment. Companies in the multiple sclerosis drugs market are regularly forced to lower the price of these drugs in order to convince their clients of their cost-effectiveness.

This research report on the APAC multiple sclerosis drugs market has been segmented and sub-segmented into the following categories:

By Drug Class:

• Interferon Beta
• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Monoclonal Antibodies
• Corticosteroids
• Adrenocorticotropic Hormone
• Others

By Disease Type:

• Relapsing-remitting MS (RRMS)
• Primary-progressive MS (PPMS)
• Secondary-progressive MS (SPMS)
• Progressive-relapsing MS (PRMS)

By Route of Administration:

• Parenteral
• Oral

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand, Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

In the APAC Multiple Sclerosis Drug market, Asia is predicted to increase at a rapid pace over the next five years. This is owing to the fact that numerous companies have built manufacturing and research facilities in the area. Low salaries, a huge talent pool, and less rigorous environmental and health, and safety standards provide this country an advantage over developed regions.

Asia's fastest-growing MS(Multiple Sclerosis) drug markets are predicted to include Japan, China, and India. The MS medicines industry would benefit from advancements in biomedical research. Some of the significant trends in the MS medicines market include increased mergers and acquisitions between manufacturing businesses and quick product releases.

KEY MARKET PLAYERS:

Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), and AbbVie, Inc. are a few of the promising companies operating in the APAC multiple sclerosis drugs market.